期刊
CLINICAL INFECTIOUS DISEASES
卷 73, 期 6, 页码 E1372-E1375出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab302
关键词
Daratumumab; hepatitis B virus; reactivation; multiple myeloma
资金
- Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea
- Research Supporting Program of The Korean Association for the Study of the Liver
- Korean Liver Foundation
Among multiple myeloma patients who are HBsAg-negative and receiving daratumumab treatment, there is a significant risk of reactivation of resolved HBV.
The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据